1296P BLU-945, a highly potent and selective 4th generation EGFR TKI for the treatment of EGFR T790M/C797S resistant NSCLC
Schalm, S.S., Dineen, T., Lim, S.M., Park, C-W., Hsieh, J., Woessner, R., Zhang, Z., Wilson, K., Eno, M., Wilson, D., Williams, B., Campbell, J., De Savi, C., Stevison, F., Utt, C., Guzi, T., Dorsch,Volume:
31
Journal:
Annals of Oncology
DOI:
10.1016/j.annonc.2020.08.1610
Date:
September, 2020
File:
PDF, 96 KB
2020